Development and validation method for the determination of atorvastatin calcium tablets drugs by using UV-spectrophotometer in pharmaceutical formulation
- 1Central laboratory, Shambat Campus, Khartoum University, Sudan
- 2Lecturar at Chemistry Department, Faculty of science, Khartoum University, Sudan
- 3Lecturar at Chemistry Department, Faculty of Pharmacy, Elrazi University, Sudan
- 4Excellece Center of Pesticide and Environmental Science, Department of crop protection, Faculty of Agriculture, Khartoum University, Sudan
- 5Central laboratory, Shambat Campus, Khartoum University, Sudan
- 6Excellece Center of Pesticide and Environmental Science, Department of crop protection, Faculty of Agriculture, Khartoum University, Sudan
Res. J. of Pharmaceutical Sci., Volume 8, Issue (1), Pages 5-14, June,30 (2019)
The objective of this research is to describe the optimization, validation, and application of spectrophotometric techniques for determination of Atorvastatin Calcium in their pharmaceutical formulation (tablets). In this paper simple, rapid, accurate and sensitive spectrophotometric methods have been developed and validated. This method is a direct spectrophotometric analytical method depend on dissolve of atorvastatin calcium in diluted anhydrous methanol methanol. The maximum absorption wavelength for determination of ATV drug was found to be 291 nanometer (nm), for Beer's law was obeyed in the concentration range from 5 to 35 µg/ml for UV- Spectrophotometric analysis method.
- Nigović B., Damić M., Injac R., Glavač N.K. and Ŝtrukelj B. (2009)., Analysis of Atorvastatin and Related Substances by MEKC., Chromatographia, 69, 1299-1305.
- Erk N. (2003)., Extractive Spectrophotometric Determination of Atorvastatin in Bulk and Pharmaceutical Formulations., Anal Lett., 36, 2699-2711.
- Castaño G., Mas R., Fernández L., Illnait J., Mesa M., Alvarez E. and Lezcay M. (2003)., Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia., Drugs Aging, 20, 153-154.
- Pfizer Ireland Pharmaceuticals (2006)., Dublin, Ireland., LAB-0021-11.0, Revised June.
- Prajapati K.P. and Bhandari A. (2011)., Spectroscopic method for estimation of atorvastatin calcium in tablet dosage form., Indo Global Journal of Pharmaceutical Sciences, 1(4), 294-299.
- Guideline I.H.T. (2005)., Validation of analytical procedures: text and methodology Q2 (R1)., In International conference on harmonization, Geneva, Switzerland, 11-12.
- All rights are reserved by Arunadevi S. Birajdar (2015)., Determination of Atorvastatin and Fenofibrate in a Fixed Dose Combination by High Pressure Liquid Chromatograph., Human Journals Research Article, 3(4). www.ijppr.humanjournals.com
- Jim Clark (2000)., The Fingerprint Region of an Infra-Red Spectrum., Chemguide, available from http:// www.che mguide.co.uk/a nalysis/ir/f ingerprint.html.
- Francis A. Carey (2000)., Organic Chemistry., 4th edition: The McGraw-Hill Companies.
- Melnikov P., Corbi P.P., Cuin A., Cavicchioli M. and Guimarães W.R. (2003)., Physicochemical properties of sildenafil citrate (Viagra) and sildenafil base., Journal of pharmaceutical sciences, 92(10), 2140-2143.
- Lever A.B.P. (1985)., Inorganic Electronic Spectroscopy., 2nd ed., Elsevier, Amsterdam, 161.
- Guideline I.H.T. (1996)., Guideline for good clinical practice E6 (R1)., ICH Harmon Tripart Guidel, 4.
- Dr. Joachim Ermer and Dr. John H. McB. Miller. (2005)., Method Validation in Pharmaceutical Analysis: A Guide to Best Practice., Wiley omline library DOI:10.1002/3527604685.
- British Pharmacopeia (BP) (2014)., Atorvastatin calcium monograph., volume II.
- Miller T.G. (1984)., Goffman, social acting, and moral behavior., Journal for the theory of social behaviour, 14(2), 141-164.
- García-Martínez J., Pelechano V. and Pérez-Ortín J.E. (2011)., Genomic-wide methods to evaluate transcription rates in yeast., Methods Mol Biol, 734, 25-44.
- United States Environmental Protection Agency, WHO, (2006)., Directed Evolution of Three Biocatalysts to Produce the Key Chiral Building Block for Atorvastatin, the Active Ingredient in Lipitor., United States Environmental Protection Agency